ALGN Stock Recent News

Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.

Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.

Align Technology (NASDAQ: ALGN), most notably the makers of Invisalign aligners specializes in orthodontic devices and restorative treatment has been through a whirlwind the past 2 years, with its stock price dropping 60% since its high in September 2021.

Align Technology manufactures 3D digital scanners and clear aligners for teeth straightening in orthodontics. ALGN's stock has seen significant volatility but has rebounded 7% YTD, with a 1-year price target of $313 per share. ALGN's international growth and strong global presence are key catalysts for driving attractive risk-reward, with a growing market for clear aligners.

Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.

Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations (I'm not sure if the metaverse qualifies right now) seek to expand in some pretty massive markets.

Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.

The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Align Technology (ALGN) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.